|Bid||2.310 x 8600|
|Ask||2.320 x 1800|
|Day's Range||2.280 - 2.350|
|52 Week Range||1.940 - 4.380|
|PE Ratio (TTM)||-3.44|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||5.25|
SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled ...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Rigel Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that Brian L. Kotzin, M.D. has been appointed to Rigel's board of directors. A well-respected former professor and clinical researcher, Dr. Kotzin brings to Rigel's board three decades of experience in the areas of immunology and inflammation. "We are excited to welcome Dr. Kotzin to our board, and we feel confident that his leadership will be of great value to Rigel," said Raul Rodriguez, president and chief executive officer of Rigel.